Mitogen-activated protein kinase kinase
(Redirected from MAP2K)
| Mitogen-activated protein kinase kinase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||
| EC no. | 2.7.12.2 | ||||||||
| Databases | |||||||||
| IntEnz | IntEnz view | ||||||||
| BRENDA | BRENDA entry | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | KEGG entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| PRIAM | profile | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| |||||||||
Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a dual-specificity kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).
MAP2K is classified as EC 2.7.12.2.
There are seven genes:
- MAP2K1 (a.k.a. MEK1)
- MAP2K2 (a.k.a. MEK2)
- MAP2K3 (a.k.a. MKK3)
- MAP2K4 (a.k.a. MKK4)
- MAP2K5 (a.k.a. MKK5)
- MAP2K6 (a.k.a. MKK6)
- MAP2K7 (a.k.a. MKK7)
The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.[1] The acronym MEK derives from MAPK/ERK Kinase.[2]
Role in melanoma
[edit | edit source]MEK is a member of the MAPK signaling cascade that is activated in melanoma.[3] When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.
See also
[edit | edit source]References
[edit | edit source]- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
External links
[edit | edit source]- Mitogen-Activated+Protein+Kinase+Kinases at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Lua error in mw.title.lua at line 392: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
